COATED SOLID PREPARATION
    1.
    发明申请
    COATED SOLID PREPARATION 有权
    涂层固体制剂

    公开(公告)号:US20120321677A1

    公开(公告)日:2012-12-20

    申请号:US13581010

    申请日:2011-02-25

    摘要: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

    摘要翻译: 含有孟鲁司特的包衣固体制剂可以应用于一剂包装,其中即使在制剂解包时也保持其中所含的孟鲁司特或其药理学上可接受的盐的湿度稳定性。 涂布的固体制剂含有作为活性成分的孟鲁司特或其药理学上可接受的盐,并且涂覆有包含聚乙烯醇和溶胀性粘土的涂层,其中上述聚乙烯醇与上述溶胀粘土的质量比 上述涂层为8:2〜3:7。

    Coated solid preparation
    2.
    发明授权
    Coated solid preparation 有权
    涂布固体制剂

    公开(公告)号:US08658208B2

    公开(公告)日:2014-02-25

    申请号:US13581010

    申请日:2011-02-25

    摘要: A montelukast-containing coated solid preparation can be applied to one-dose package, wherein the humidity stability of montelukast or a pharmacologically acceptable salt thereof contained therein is maintained even when the preparation is unpacked. A coated solid preparation contains as an active ingredient montelukast or a pharmacologically acceptable salt thereof and is coated with a coating layer comprising polyvinyl alcohol and swelling clay, wherein the mass ratio of the above-described polyvinyl alcohol to the above-described swelling clay in the above-described coating layer is 8:2 to 3:7.

    摘要翻译: 含有孟鲁司特的包衣固体制剂可以应用于一剂包装,其中即使在制剂解包时也保持其中所含的孟鲁司特或其药理学上可接受的盐的湿度稳定性。 涂布的固体制剂含有作为活性成分的孟鲁司特或其药理学上可接受的盐,并且涂覆有包含聚乙烯醇和溶胀性粘土的涂层,其中上述聚乙烯醇与上述溶胀粘土的质量比 上述涂层为8:2〜3:7。

    Coated solid preparation
    4.
    发明授权
    Coated solid preparation 有权
    涂布固体制剂

    公开(公告)号:US08652521B2

    公开(公告)日:2014-02-18

    申请号:US13201546

    申请日:2010-03-03

    IPC分类号: A61K31/19 A61K9/32

    摘要: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.

    摘要翻译: 包衣固体制剂包括包括丙戊酸或其药理学上可接受的盐的活性成分,以及包含聚乙烯醇和膨胀粘土的涂层,其中涂覆有活性成分,其中聚乙烯醇与膨胀粘土的质量比为8:2至3:1。 并且膨胀粘土作为层压结构分散。

    COATED SOLID PREPARATION
    5.
    发明申请
    COATED SOLID PREPARATION 有权
    涂层固体制剂

    公开(公告)号:US20110305756A1

    公开(公告)日:2011-12-15

    申请号:US13201546

    申请日:2010-03-03

    IPC分类号: A61K9/24 A61P25/08 A61K31/19

    摘要: A coated solid preparation includes an active ingredient including valproic acid or a pharmacologically acceptable salt thereof, and a coating layer containing polyvinyl alcohol and swelling clay coating the active ingredient wherein mass ratio of the polyvinyl alcohol to the swelling clay is 8:2 to 3:7 and the swelling clay is dispersed as a laminated structure.

    摘要翻译: 包衣固体制剂包括包括丙戊酸或其药理学上可接受的盐的活性成分,以及包含聚乙烯醇和膨胀粘土的涂层,其中涂覆有活性成分,其中聚乙烯醇与膨胀粘土的质量比为8:2至3:1。 并且膨胀粘土作为层压结构分散。

    Preparation for percutaneous absorption
    6.
    发明授权
    Preparation for percutaneous absorption 失效
    经皮吸收制剂

    公开(公告)号:US5854281A

    公开(公告)日:1998-12-29

    申请号:US676250

    申请日:1996-12-10

    摘要: The present invention provides a preparation for percutaneous absorption comprising as an effective component a prostaglandin I.sub.2 derivative and a fatty acid or a derivative thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. Particularly, the present invention provides a preparation for percutaneous absorption comprising 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative and a C.sub.6 -C.sub.24 fatty acid, a salt thereof or an ester thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. This preparation for percutaneous absorption suggests a possibility to last pharmacological effects and to reduce side effects. Thus, the preparation is expected to be used for therapy of various diseases, aiming at topical and systemic actions.

    摘要翻译: PCT No.PCT / JP95 / 02350 Sec。 371日期1996年12月10日第 102(e)日期1996年12月10日PCT 1995年11月16日PCT PCT。 WO96 / 15793 PCT出版物 日期:1996年5月30日本发明提供一种经皮吸收制剂,其含有作为有效成分的前列腺素I2衍生物和脂肪酸或其衍生物,或其两种以上的混合物,其具有PGI2衍生物的高经皮渗透性 。 特别地,本发明提供了一种经皮吸收制剂,包括5,6,7-三硝基-4,​​8-​​间间苯二胺PGI 2衍生物和C 6 -C 24脂肪酸,其盐或其酯或其混合物 的两种或更多种,其具有PGI2衍生物的高经皮渗透性。 用于经皮吸收的这种制剂表明可能会持续药理作用并减少副作用。 因此,该制剂预期用于各种疾病的治疗,旨在局部和全身性的作用。

    Transmitter-receiver for electronic mail that provides convenience to a user receiving mail services from various mail service providers at different terminals and different places
    7.
    发明授权
    Transmitter-receiver for electronic mail that provides convenience to a user receiving mail services from various mail service providers at different terminals and different places 失效
    用于电子邮件的发送器 - 接收器,其为在不同终端和不同地点的各种邮件服务提供商接收邮件服务的用户提供方便

    公开(公告)号:US06272530B1

    公开(公告)日:2001-08-07

    申请号:US08873561

    申请日:1997-06-12

    IPC分类号: G06F1516

    摘要: The object of the present invention is to provide A transmitter-receiver enables a user to send a mail in an optimal mode even to a portable terminal with lower functional capability without a need for awareness of a plurality of mail service providers. The transmitter-receiver notifies of arrival of the mail at an optimal communication cost depending on the importance of the mail, and unifies a plurality of mail spools. The unified mail spools are controlled by a spool integration unit. The transmitter-receiver according to the present invention comprises a terminal response unit for inquiring capability of a user terminal and a data form converting unit, and the mail is sent in an optimal form to the user terminal. In case the content of the mail cannot be read perfectly, it is designed in such manner that the mail is not deleted from the spool, and arrival of the mail is notified to the user at an optimal communication cost depending on the importance of the mail and position information of the user.

    摘要翻译: 本发明的目的是提供一种发送器 - 接收器,使得用户能够以更低的功能能力即时发送具有最佳模式的邮件到便携式终端,而不需要对多个邮件服务提供商的意识。 发射机 - 接收机根据邮件的重要性以最佳通信费用通知邮件的到达,并且统一多个邮件线轴。 统一邮件线轴由线轴集成单元控制。 根据本发明的发射机 - 接收机包括用于查询用户终端和数据表转换单元的能力的终端响应单元,并且邮件以最佳形式发送给用户终端。 在邮件的内容不能完美地读取的情况下,其设计方式是邮件不从假脱机中删除,并且根据邮件的重要性将邮件的到达以最佳的通信费用通知给用户 和用户的位置信息。

    Information acquisition proxy system and information transfer managing
system
    8.
    发明授权
    Information acquisition proxy system and information transfer managing system 失效
    信息采集代理系统和信息传递管理系统

    公开(公告)号:US6085239A

    公开(公告)日:2000-07-04

    申请号:US958318

    申请日:1997-10-27

    IPC分类号: G06F12/00 G06F13/00 G06F17/30

    CPC分类号: G06F17/3089

    摘要: An information acquisition proxy system which conducts mediation for information acquisition between an information accessing terminal and an information distributing server. The system comprises a user authentication section for identifying a user and an information acquisition history managing section for retaining and managing a demand for information acquisition from the information accessing terminal, with the information acquisition history managing section retaining and managing demands in units of users. Also included in the system is an additional information managing section for managing additional information for the demand said information acquisition history managing section manages. With this arrangement, an additional information is added by one user when the user has access to specific information, and hence the user can refer to the additional information at the later information access using a different information accessing terminal, thus allowing effective information access work based upon the previous access situation.

    摘要翻译: 一种信息获取代理系统,用于在信息访问终端和信息分发服务器之间进行信息获取中介。 该系统包括用于识别用户的用户认证部分和用于从信息访问终端保持和管理对信息获取的需求的信息获取历史管理部分,信息获取历史管理部分以用户为单位保存和管理需求。 还包括在系统中的附加信息管理部分用于管理所述信息获取历史管理部分管理的需求的附加信息。 利用这种安排,当用户访问特定信息时,由一个用户添加附加信息,因此用户可以使用不同的信息访问终端在稍后的信息访问中参考附加信息,从而允许有效的信息访问工作 以前的访问情况。

    Stable tablet containing 4,5-epoxymorphinan derivative
    9.
    发明授权
    Stable tablet containing 4,5-epoxymorphinan derivative 有权
    含有4,5-环氧吗啡喃衍生物的稳定片剂

    公开(公告)号:US08829019B2

    公开(公告)日:2014-09-09

    申请号:US13125726

    申请日:2009-10-23

    摘要: The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient.

    摘要翻译: 本发明涉及包含4,5-环氧吗啡喃衍生物或其药理学上可接受的酸加成盐作为有效成分的稳定片剂。 也就是说,根据本发明的片剂包括:(1)作为有效成分的特定的4,5-环氧吗啡喃衍生物或药理学上可接受的酸加成盐; (2)硫代硫酸钠; (3)选自糖和糖醇的至少一种; 和(4)交聚维酮,羧甲基淀粉钠或其混合物,其中上述(4)的含量为含有上述有效成分的每单位重量的1至20重量%。